CareDx (NASDAQ:CDNA) used an investor webcast to outline its “Transplant Plus” expansion into cell therapy and to highlight new data supporting AlloHeme, a blood-based test designed to predict relapse following allogeneic hematopoietic cell transplantation (HCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Positioning AlloHeme within CareDx’s broader strategy President and CEO John Hanna […]